Syros Pharmaceuticals Inc (NAS:SYRS)
$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Syros Pharmaceuticals Inc SY-2101 in APL-Call Transcript

Jul 20, 2021 / 12:30PM GMT
Release Date Price: $49.2 (+1.03%)
Operator

Good day, and thank you for standing by. Welcome to the Syros Pharmaceuticals Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Nancy Simonian. Chief Executive Officer of Syros. Please go ahead.

Nancy A. Simonian
Syros Pharmaceuticals, Inc. - President, CEO, Interim Principal Financial & Accounting Officer and Director

Thank you. Good morning, and welcome to our KOL webinar on SY-2101 in APL. We will be making forward-looking statements. You can find a full description of our risk factors on our website.

Slide 3. Today is the third in a series of KOL events on our targeted heme portfolio. We are very pleased to have Dr. Farhad Ravandi, Professor of Medicine and Chief of Section of AML in the Department of Leukemia at the MD Anderson Cancer Center as our guest speaker today.

Slide 4, today's agenda. I will be making a few opening remarks Dr. Ravandi will discuss the treatment landscape and unmet need in APL. David Roth, our CMO, will give an overview of SY-2101 in APL, and we will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot